Compare SOPH & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | PROF |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 230.4M |
| IPO Year | 2021 | N/A |
| Metric | SOPH | PROF |
|---|---|---|
| Price | $4.51 | $7.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $11.00 |
| AVG Volume (30 Days) | 76.0K | ★ 150.0K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,297,000.00 | $14,297,000.00 |
| Revenue This Year | $18.32 | $64.23 |
| Revenue Next Year | $15.61 | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.66 | ★ 67.94 |
| 52 Week Low | $2.58 | $3.76 |
| 52 Week High | $5.30 | $7.99 |
| Indicator | SOPH | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 60.31 |
| Support Level | $4.60 | $7.02 |
| Resistance Level | $4.84 | $7.75 |
| Average True Range (ATR) | 0.23 | 0.40 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 17.51 | 69.66 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.